Greg Motz

Greg Motz serves as Vice President of Immunology at BlueRock Therapeutics since July 2021. Previously, Greg held the position of Vice President and Head of Biology at Orna Therapeutics, Inc., where leadership of the biology team contributed to the advancement of a circular RNA platform and supported funding efforts amounting to $100 million in Series A. Prior to that role, Greg was at Unum Therapeutics from 2016 to 2020, where responsibilities ranged from Senior Director, Head of Research to Principal Scientist in Immunopharmacology, overseeing a team of 12 scientists in developing novel T-cell therapies for oncology. Earlier experience includes an Investigator II role at Novartis, where Greg led the discovery of CAR-T therapies and managed a small team of research scientists.